Merck & CompanyvsRoyalty Pharma

MRK and RPRX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Merck & Company (MRK) has a market value of $341B and Royalty Pharma (RPRX) $29.5B. Over the last year, with dividends, MRK moved +52.7% and RPRX +78.4%. The P/E is 138.9 for MRK and 43.9 for RPRX. Dividend yield: MRK 2.47%, RPRX 1.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$341B

    RPRX$29.5B

    MRK is 12 times RPRX

  • Revenue, 12 months

    MRK$67.4B

    RPRX$2.6B

    MRK is 26 times RPRX

  • Net income, 12 months

    MRK$2.5B

    RPRX$672M

    MRK is 3.6 times RPRX

  • Operating margin

    MRK–

    RPRX57.1%

  • ROIC

    MRK3.9%

    RPRX6.3%

    2.4 points apart

  • P/E

    MRK138.9

    RPRX43.9

    MRK is 3.2 times RPRX

  • Dividend yield

    MRK2.5%

    RPRX1.4%

    1.1 points apart

  • 5-year return

    MRK+94.3%

    RPRX+82.2%

    12.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+94.3%

RPRX+82.2%

10015020020222023202420252026
Returns by period
PeriodMRKWith dividendsRPRXWith dividends
1 year since November 17, 2025+52.7%Price +48.4%+78.4%Price +75.4%
3 years since November 17, 2023+48.4%+14.1% a yearPrice +35.4%+177.4%+40.5% a yearPrice +158.2%
5 years since November 17, 2021+94.3%+14.2% a yearPrice +66.8%+82.2%+12.8% a yearPrice +61.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyRPRXRoyalty Pharma

Valuation

MRKRPRX
Valuation
Price$137.78$68.67
Market value$341B$29.5B
Enterprise value (EV)$385B$37.6B
P/E138.943.9
P/E, 5-year median14.817.5
P/B7.63.0
EV/EBIT80.825.1
Free cash flow yield4.3%10.0%

Results and growth

MRKRPRX
Results and growth
Revenue, 12 months$67.4B$2.6B
Net income, 12 months$2.5B$672M
Free cash flow, 12 months$14.7B$3.0B
Earnings per share, 12 months$0.98$1.53
Revenue growth, year on year1.3%5.1%
Revenue growth a year, past+9.4%over 5 years+2.3%over 5 years
EPS growth a year, past+21.2%over 5 years+6.2%over 5 years

Margins and returns on capital

MRKRPRX
Margins and returns on capital
Gross margin71.8%–
Operating margin–57.1%
Net margin3.6%25.7%
ROIC3.9%6.3%
ROE5.2%6.9%

Balance sheet

MRKRPRX
Balance sheet
Cash$9.7B$545M
Total debt$53.8B$8.6B
Net debt / EBITDA5.75.4
Interest cover2.4×4.0×

Dividends and buybacks

MRKRPRX
Dividends and buybacks
Dividend yield2.5%1.4%
Dividend per share, 12 months$3.40$0.94
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%4.2%
Shareholder yield4.0%5.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or RPRX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Royalty Pharma?

By market value, Merck & Company ($341B) is about 11.5 times Royalty Pharma ($29.5B), at today's prices.

How did MRK and RPRX stock do over the last 5 years?

Since November 17, 2021, MRK's price moved +66.8% and RPRX's +61.7%. With dividends: MRK +94.3% (+14.2% a year), RPRX +82.2% (+12.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or RPRX?

The dividend yield at today's price is 2.47% for Merck & Company and 1.37% for Royalty Pharma. Over the last twelve months they paid $3.40 and $0.94 per share.

What is the P/E of MRK and RPRX?

At today's price, the P/E is 138.9 for MRK and 43.9 for RPRX. The median of the last five years was 14.8 and 17.5, which shows where each stands against its own past.

Which has the higher profit margins, Merck & Company or Royalty Pharma?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 25.7% for Royalty Pharma, and the operating margin – and 57.1%. Revenue was $67.4B and $2.6B.

Which is the better investment, Merck & Company or Royalty Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.